Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

Launched by HOSPITAL DO RIM E HIPERTENSÃO · Mar 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called Letermovir to help prevent cytomegalovirus (CMV) infection in people who have received a kidney transplant. CMV is a common virus that can cause serious problems for transplant recipients, so finding effective ways to prevent it is very important. The trial will look at whether Letermovir can safely reduce the risk of CMV infection compared to other methods, which sometimes have side effects like lowering white blood cell counts.

To participate in the trial, you need to be at least 18 years old and have received a kidney transplant or a second kidney transplant. You should also be receiving certain types of medications after your transplant. However, if your donor tested positive for CMV and you did not, or if you are receiving multiple organs, you won’t be eligible for this trial. Participants will be monitored closely throughout the study to see how well the medication works and to check for any side effects. This trial is not yet recruiting, but it’s an important step toward improving care for kidney transplant recipients at risk for CMV infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Kidney transplant or re-transplant recipients, aged ≥18 years;
• • Undergoing induction therapy with anti-thymocyte globulin;
• • Receiving maintenance treatment with Tacrolimus, Mycophenolate and Prednisone;
• • Positive CMV serology for donor and recipient.
• Exclusion Criteria:
• • CMV serology positive for donor and negative for recipient;
• • Multiple organ recipients, or other organs